ADAG Adagene (ADAG) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001818838
Cluster · 3 insidersC-suite buying · 2Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter
What the filings say about ADAG
Insiders, 180 days
+$162.2K net bought
3 buyers
Planned sales (Form 144), 90 days
$158.0K
1 notice
Adagene insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Adagene Inc. insiders bought a net $162.2K of stock across 5 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.7% of the 12,000 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Tam Man Kin bought about $6.0K of ADAG on Sep 23, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 5, 2026.
- The trade is 22.9% of the 88,535 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Luo Peter bought about $64.0K of ADAG on Sep 16, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 2,000 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DO CUONG V bought about $7.5K of ADAG on Aug 14, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 4, 2026.
- The trade is 0.4% of the 68,245 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Luo Peter bought about $1.0K of ADAG on Aug 5, 2026; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.8% of the 67,966 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Luo Peter bought about $83.7K of ADAG on Aug 4, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$162.2K over 180 days
+$162.2K over 90 days
more than 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
+7332.8% year over year
more than 99% of Pharma & Biotech
Margin
-229.6% net margin
below 67% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.7% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
below 56% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders bought a net $162.2K while the stock fell 30% over six months, but 1 Form 144 notice ($158.0K) are queued to sell.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ADAG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+43.1%12M
Insider buyForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ADAG: institutional holders (13F)
13F holdings, latest reported quarter
6,666,666 sh
$28.1M
2,666,666 sh
$11.2M
2,666,666 sh
$11.2M
1,716,711 sh
$7.2M
1,343,364 sh
$5.6M
Congress trades in ADAG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ADAG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
GU CHUNFANG
Filed 2026-08-19
$158.0K
ADAG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Golden Dragon China ETF
$158.6K position · as of 2026-07-31
0.2%
Fidelity Nasdaq Composite Index Fund
$40.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $162.2K bought by insiders over 180 days, 26 funds added last quarter, $158.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ADAG financials
Revenue growth
+7332.8%
XBRL, annual
Net margin
-229.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Debt to equity
0.17x
long-term 2025-12-31 plus current 2025-12-31; equity 2025-12-31
Debt to equity ADAG
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.36x |
| FY Dec 2023 | 0.31x |
| FY Dec 2022 | 0.33x |
| FY Dec 2021 | 0.05x |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$79.1M
market value at close 2026-10-26 on 2025-12-31 shares, plus long-term 2025-12-31 plus current 2025-12-31, minus cash 2025-12-31
Enterprise value ADAG
| FY Dec 2025 | $43.5M |
| FY Dec 2024 | $50.2M |
| FY Dec 2023 | $18.5M |
| FY Dec 2022 | -$44.4M |
| FY Dec 2021 | $273.6M |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing ADAG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $7.7M | $103.2K | $18.1M | $9.3M |
| Operating income | -$21.4M | -$36.0M | -$23.7M | -$83.9M |
| Net income | -$17.6M | -$33.4M | -$18.9M | -$80.0M |
| EPS (diluted) | -0.30 | -0.59 | -0.35 | -0.31 |
| Operating cash flow | -$15.7M | -$29.7M | -$28.5M | -$48.6M |
| Cash | $74.5M | $85.2M | $109.9M | $143.8M |
| Long-term debt | $1.1M | $417.3K | $13.5M | $14.1M |
| Buybacks | n/a | n/a | n/a | $4.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
ADAG Stock Sonar score 5/7 axes
Find similar shapesCompareADAG ranks highest on growth (99th percentile) and insider conviction (84th), and lowest on institutional and government (36th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ADAG filings, in plain words
Are Adagene insiders buying or selling ADAG?
In the 180 days to 2026-10-27, Adagene insiders were net buyers, a net $162.2K across purchases and sales reported on Form 4, by 3 buyers.
Are there planned insider sales of ADAG?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $158.0K of stock; the latest, by GU CHUNFANG, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-27, Adagene insiders were net buyers of ADAG, a net $162.2K across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $158.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
